BETTERHEALTH: WEEKLY LINKEDIN LIVE WEBINARS
“BetterHealth” Webinar: Closer Than Ever to a Cure for Cancer
Ian Akash Morrison Co-Founder and CEO and Barthalomew Sillah, MD, MBA
COO of Avesta76 will be talking about how incredible NEXT GENERATION CANCER THERAPY may unlock the Cure for Cancer
Many diseases including cancers today don’t have a cure. But maybe it doesn’t have to be that way.
With advances in research and development and new technologies, we may be closer than ever to a cure for cancer.
https://www.linkedin.com/video/event/urn:li:ugcPost:7045265371150319616/
Tuesday March 28th 12:00 PM EST
Hosted by Endeavor Funds & Venture Studio I
Endeavor Life Sciences Growth Advisors
Accelerating Innovation and Healthcare Solutions
Moderated by:
Dr. Martin Gershon
Managing Partner and CIO
Endeavor Venture Funds & Venture Studio
Endeavor Life Sciences Growth Advisors
martin@gershoncapital.com
Featured Speakers:
Ian Akash Morrison
Co-Founder and CEO Avesta76
Barthalomew Sillah, MD, MBA
COO Avesta76
EACH TUESDAY 12-1245PM EST, we will bring you a new, exciting “BetterHealth” Live Event featuring speakers, panel discussions and live audience questions on healthcare innovation and how it impacts you to bring you better health.
WE RECOGNIZE that we are at the cusp of the 4th Industrial Revolution, where advances in technology, medicine and science will significantly accelerate the development of new novel drugs, devices, services and our own overall personal well being and health status.
WE BELIEVE that groundbreaking new technologies such as AI, Machine Learning, Deep Learning, 3D printing, and gene editing software are intersecting with the unprecedented advances in healthcare and life sciences research, dramatically reshaping drug discovery, diagnostic testing and predictive medicine, personalized medicine and the entire healthcare system and all of our lives.
BUT THIS IS JUST THE BEGINNING. There’s been $100 billion in investments to date in innovation and technology in healthcare and life sciences.
IN OUR WEBINAR TODAY
When you have Cancer, or care about someone who does, “Cure” may be the word you want to hear more than any other. It’s also a word most doctors won’t say.
Unlike other diseases, cancer has its own language: There’s no cure for it, but there are treatments that may be able to cure some people of some cancers.
When you have cancer, abnormal cells develop, divide, and destroy healthy tissue in your body. Some types grow slowly; others spread quickly. Each kind starts in a different part of your body and has its own grades, stages, and symptoms.
Because every kind of cancer is different, there’s no one-size-fits-all cure.
But maybe that’s no longer true?
Maybe a young emerging healthcare company is ready to turn the medical world upside down with its new discovery that allows us to wipe out the central artery of all cancers.
Avesta76 is a discovery stage biotechnology company run by an outstanding team of researchers, scientists, and business savvy professionals that have discovered a protein RLIP76 that is ubiquitous in all our cells that when turned off, stops cancer from ever starting.
The company has data that shows that by turning off the function of this protein, healthy cells continue to live and grow, but even in the face of highly carcinogenic materials, cancer cells don’t develop or spread. Moreover, if the protein is allowed to develop and increase in concentration, tumor cells appear.
Could it be that Avesta76 has discovered the unifying key to unlock the cure for cancer? Or more to the point, the key that never lets cancer begin to form.
Today we will hear from the Co-Founder and CEO Ian Akash Morrison whose grandfather first began this research and who is passionate about eradicating cancer in our lifetime. And you will hear from the COO Barthalomew Sillaha whose business acumen and medical and scientific background support the mission driven journey of the company.
Endeavor Venture Fund & Venture Lab I Endeavor Life Sciences Growth Advisors is proud to support these efforts and applauds this incredible research.
Newsletter: SUBSCRIBE@GERSHONCAPITAL.COM
Healthcare Innovation & Technology Conference October 27th 2022
Sponsored by Harvard in Technology Alumni Association, Capgemini, Torreya Partners, Endeavor Life Science Funds, Harvard Business School Healthcare Alumni Association
We are proud to announce an exciting event on The Future of Healthcare Innovation and Technology, Oct 27th in NYC by Harvard Alumni in Tech sponsored by Torreya Partners and Capgemini and co-sponsored by HBS Healthcare Alumni Association and NYCHBL and moderated by Dr. D. Martin Gershon founder of Endeavor Life Science Funds, and a Leading Life Science Innovation Strategist, and Advisor to Harvard Innovation Labs (www.linkedin.com/in/dmartingershonmd)
The upcoming Healthcare Innovation and Technology Conference will include an exciting new panelist Dr Fahimeh Sasan from Kindbody talking about incredible advances in womens healthcare as well as the other discussions highlighting trends in investment and start-ups that are leveraging groundbreaking scientific discoveries and technology to build companies that are disruptive, changing the landscape of healthcare to improve healthcare for everyone.
There will be an exciting spotlight in the conference on the intersection of technology and healthcare with a focus on the four key verticals that Big Tech companies like Google, Microsoft, Amazon and Apple are investing billions in: AI-Machine Learning, Drug Discovery including 3D Printing of Human Tissues and Organs, Wearable Sensors in Health and Wellness and Diagnostics, and Digital Healthcare improving Access to Healthcare and improved treatment
Additionally there will be a fireside chat with two young emerging entrepreneurs Eli and Zach Dorf who are designing the next world class digital pharmacy platform designed to be the Shopify of drug sales.
The 300 attendees will include Amazon, Apple, Microsoft, Nvidia, Pfizer, Lilly, Google and Boehringer Ingelheim, Novartis, Alumni Ventures, BlackRock
https://www.eventbrite.com/e/423685884887
Big Tech Companies are Driving a New Secular Growth Industry in Healthcare
Every fall, hundreds of recent graduates and Harvard alumni who have moved into NYC attend our “Welcome to NYC Mixer” to join the Harvard in Tech community. This year, our event will focus on identifying trends in investment and startups that are leveraging groundbreaking scientific discoveries in the healthcare space.
There will be an exciting focus on the intersection of technology and healthcare, with a focus on Digital Healthcare, AI, and the delivery of virtual healthcare services that are democratizing healthcare. There will be a discussion on how AI driven diagnostics are improving the accuracy of diagnoses, AI and Machine Learning applications are designing new treatment algorithms that improve outcomes, and the 3D printing of human tissues are allowing for drug discovery and development to be faster and more predictive of real-world effects.
Date: October 27th, 6PM-9PM
Location: Capgemini 79 5th Avenue, 2nd floor, New York, NY, 10003
Schedule:
6:00pm: Doors Open
Keynote Speaker: Tim Opler on the exciting companies being developed in healthcare leveraging groundbreaking new technology and innovation
6:15pm : Panel + Q&A with Dr. D. Martin Gershon, Bunny Ellerin, William Haseltine, Mike Graffeo, Dr. Fahimeh Sasan
7:15pm: Networking
9:00pm: Event ends
LIVE STREAMING FOR THE EVENT WILL BE AVAILABLE FOR REGISTERED ATTENDEES
Dr. Martin Gershon, MD, JD, MPH (moderator): Managing Partner, Endeavor Life Science Funds https://www.linkedin.com/in/martingershonmd/ www.gershoncapital.com
Dr. Martin Gershon is a Leading Healthcare Innovation Strategist and Advisor for Fortune 500 Companies, Venture Capital and Angel investor, a designated Standard & Poor’s Healthcare Industry Leader, Google Scholar in Healthcare Economics and Finance, former Pictet Asset Management Advisory Board Member, Chairman of the Aspen Institute Business of Health Program and Aspen Institute Senior Fellow, Memorial Sloan-Kettering Cancer Center Mayday Fellow, Advisor to the Harvard Innovation Labs, an active member of Harvard Business School Healthcare Alumni Association, Harvard Alumni in Technology Association, and Harvard Business School Alumni Venture Capital and Private Equity Association, and has 20 years of experience as a neuroscientist, oncologist/immunologist, healthcare economist, and FDA healthcare regulatory attorney.
Dr. Gershon founded the Endeavor Life Science Fund in 2009 investing in groundbreaking companies like Moderna and 69 late stage life science companies that possess innovative and disruptive technologies with strong scalable commercial potential and social impact. In 2022 Dr. Gershon established a new Accelerator and Family Fund, Endeavor Life Science Fund II, targeting investments into 100 early stage healthcare companies that are driven by great entrepreneur/founders with cutting edge innovation that look for mentoring, coaching and strategic partnerships to build their early stage companies into the next unicorns.
Dr. Gershon has served as a Senior Life Science Advisor of Strategic Partnerships and Commercialization including Go-to-Market strategies/FDA approval/Pricing and Reimbursement, to McKinsey. Goldman Sachs, Bain Capital, TPG, BlackRock,Tiger Global, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Novartis, American Express, Bill and Melinda Gates Foundation, and the Rockefeller Foundation. He has been featured as a leading expert in healthcare innovation and investment on CNBC, and has been a speaker at numerous conferences including the Harvard Business School Health Industry Alumni Conference, Healthcare M&A Corporate Development Conference, Investment and M&A Opportunities in Healthcare Conference, and the Healthcare Deal Making Summit.
Dr. Gershon has been an Adjunct Professor of Healthcare Economics and Policy at Johns Hopkins University, Guest Lecturer of Healthcare Finance and Drug Development at Harvard University and MIT Sloan Business School, Assistant Professor of Healthcare Economics and Finance at Columbia University, Visiting Scholar Lecturer of Healthcare Economics and Policy at McGill University, and is the recipient of the Ciba-Geigy Outstanding Researcher Award in Oncology and Immunology.
Keynote Speaker: Tim Opler, Ph.D.
Tim Opler, Ph.D. Partner and Co-Founder New York Office | tim.opler@torreya.com
Tim Opler, Partner and Co-Founder of Torreya, manages client relationships and oversees the firm’s administrative activities. Tim has 24 years experience leading strategic and financing transactions across multiple sectors. For nearly 20 years, he has focused exclusively on life sciences advisory; he has completed more than 150 financing, licensing, and M&A transactions across the industry with a total value of over $100 billion. Highlights include running the largest share buyback in history for Pfizer, leading a $3.9 billion convertible bond exchange for Amgen, working on Chiron’s $5.1 billion sale to Novartis, and managing Genentech’s inaugural $2 billion bond issue.
Before co-founding Torreya, Tim was Vice President of Strategy at FibroGen, where he helped raise $117 million for the company and negotiated licensing deals. Previously, Tim was a Managing Director in Healthcare Investment Banking at Credit Suisse First Boston and held senior roles at W.R. Hambrecht, Deutsche Bank, and Merrill Lynch.
Other notable transactions on which Tim advised prior to starting Torreya include advising Pfizer on the sales of Heumann, Dorom, and NM Pharma; managing $1.1 billion in swaps and bond issues for Eli Lilly; managing $150 million in derivatives for Guidant; managing $850 million in bond issuance and swaps for Bristol-Myers Squibb; acting as a lead on Glaxo’s $1 billion bond issue; and leading a $600 million Eurobond issue for Pfizer. He has also led transactions and served as a strategic advisor for BHP, BMW, BP, Coca-Cola Enterprises, Daimler, Dell, Diageo, Dow, Ford, GE, GM, the State of Israel, Microsoft, Philip Morris, the State of Poland, and Royal Dutch Shell, among others.
Prior to his career in investment banking, Tim was a professor in the finance department at Ohio State University. He earned a B.S. in economics and philosophy from Florida State University, and a Ph.D. in economics from UCLA.
Panelists:
Bunny Ellerin, MBA, HBS Healthcare Alumni President / CEO NYC Healthcare Business Leaders (co-sponsor)
Bunny is a Harvard-trained, award-winning healthcare leader, entrepreneur and influencer who has dedicated her career to driving change and innovation in healthcare. Successful across entrepreneurial, corporate, and academic settings, she is highly regarded for her industry expertise and extensive network. She has become a recognized force in leading New York City’s transformation into a thriving hub of healthcare innovation. An expert in digital health, Bunny has her pulse on — and relationships to — the companies and people defining healthcare’s future.
Bunny co-founded and serves as CEO of NYC Health Business Leaders (NYCHBL), the premier network of 5,000+ senior-level professionals, executives, entrepreneurs and leaders engaged in New York’s healthcare ecosystem. Founded in 2009, the organization has played a key role in turning the city into a healthcare epicenter. What sets NYCHBL apart from other organizations is its focus on the people and companies driving the innovation – we support and promote their success. NYCHBL started as a convener, yet it has become so much more – a trusted source of quality content, networking and leadership, including the renowned New York Healthcare Innovation reports and NYC Digital Health 100.
William Haseltine, PhD, a scientist, businessman, author, and philanthropist. He is known for his groundbreaking work on HIV/AIDS and the human genome
William A. Haseltine is an American scientist, businessman, author, and philanthropist. He is known for his groundbreaking work on HIV/AIDS and the human genome. Haseltine was a professor at Harvard Medical School where he founded two research departments on cancer and HIV/AIDS. Haseltine is a founder of several biotechnology companies including Cambridge Biosciences, The Virus Research Institute, ProScript, LeukoSite, Dendreon, Diversa, X-VAX, and Demetrix. He was a founder chairman and CEO of Human Genome Sciences, a company that pioneered the application of genomics to drug discovery. He is the president of the Haseltine Foundation for Science and the Arts and is the founder, chairman, and president of ACCESS Health International, a not-for-profit organization dedicated to improving access to high-quality health worldwide. He was listed by Time Magazine as one of the world’s 25 most influential business people in 2001 and one of the 100 most influential leaders in biotechnology by Scientific American in 2015.
Mike Graffeo, MBA (Fluidform CEO ), 3D Printing Company that prints human heart tissue
Mike Graffeo is the CEO of Fluidform with a proven track record in the commercialization of innovative medical technology. Mike is a results-oriented, decisive leader with a track record of successfully growing new businesses in both startup and growth organizations. Throughout his career, he has gained extensive experience translating highly complex devices and clinical data into successful businesses, both in the US and globally. Mike holds a BS in Engineering Physics and an M.Eng in Mechanical Engineering from Cornell University, as well as an MBA with high distinction (Baker Scholar) from Harvard Business School.
Dr. Fahimeh Sasan, MD (kindbody Founding Physician and Chief Innovation Officer), Leading women’s health provider of fertility and wellness services.
Dr. Fahimeh Sasan is Chief Innovation Officer at Kindbody where she builds and leads programs that help employers deliver equitable and inclusive family-building benefits programs to their global workforces. Kindbody is a leading fertility clinic network and family-building benefits provider for employers offering comprehensive virtual and in-person care.
Dr. Fahimeh Sasan is a board certified Ob/Gyn who completed her residency in obstetrics and gynecology at Mount Sinai Hospital in New York City. In addition to her work at Kindbody, Dr. Sasan is an Assistant Professor of Obstetrics, Gynecology, and Reproductive Medicine at Mount Sinai Hospital in New York.
As a practicing clinician for more than 15 years she is dedicated to helping her patients with comprehensive care with a focus on providing an exceptional, personalized experience. Dr. Sasan and her team provide fertility services, gynecology, low-risk and high-risk prenatal care, and wellness support, offering patients a single door for all of their fertility healthcare needs. Dr. Sasan is a recognized and widely-quoted expert on fertility healthcare and education in the media including NBC News, CBS News, and TODAY.
Hosted by Harvard in Tech
Founded in 2013, Harvard in Tech is Harvard University’s official Alumni Group for technology. Our mission is to further the development of technology through encouraging innovation, providing Harvard alumni technologists with resources and networks, and promoting technological activity throughout the Harvard community. We have hosted 100+ events for 10,000+ alumni & friends across 5 major cities. Join our mailing list to receive invitations to future events: www.harvardintech.com
This event is made possible by our sponsors:
Torreya Partners
Torreya is a global investment banking boutique serving companies in the life sciences industry. Since our inception in 2007, we have advised clients on more than $100 billion worth of deals for biotechnology, branded pharmaceutical, generic pharmaceutical, and life sciences companies. Our partners are senior industry bankers and executives, with deep experience, knowledge, and networks. We are a partner of choice for companies seeking discreet, conflict-free, and knowledgeable advice on M&A, pharmaceutical asset sale, capital markets, and licensing transactions.
Torreya is differentiated from most other life sciences advisory practices by the breadth of its global presence. Over half the transactions on which we advise are cross-border. Torreya has offices in London, Mumbai, and New York, and affiliate offices on six continents.
Capgemini
Capgemini is the strategic partner who will help you ask the tough questions – and find the right answers – by harnessing the power of technology. We apply a breadth of expertise to address the full range of business needs across four areas: Strategy and transformation, applications and technology, engineering, and operations. We focus on helping drive value in three key areas: customer experience, intelligent industry, and enterprise management. As we do this, we help our clients embrace key technologies such as cloud, data, and artificial intelligence, and also work to improve their cybersecurity and environmental impact.
We focus on three ‘playing fields’ dedicated to the digitalization of key management areas at the core of businesses: Customer First, Intelligent Industry, and Enterprise Management. This is underpinned by two technological pillars essential to all forms of digital transformation – data and cloud, without losing sight of the fundamentals of cybersecurity and sustainable development.
Thanks to deep, sector-specific expertise, we are able to develop solutions that are aligned to our clients’ unique challenges and can help them meet their specific objectives.
There isn’t just one road to the cloud – you need to choose the route that’s right for you. With us, establish a digital foundation that’s tailored to your needs, building on it with automation, analytics, artificial intelligence, and more.
We combine our end-to-end cloud services with sector-specific expertise, advanced cloud technologies and global resources to guide your cloud journey every step of the way. And our strong partnerships with the world’s leading hyperscalers means we can harness their innovations to accelerate yours.
We offer three core categories of cloud services to maximize the business outcomes of cloud adoption: Cloud for customer first; cloud for enterprise management, and cloud for intelligent enterprise.
- Create personalized and satisfying experiences by leveraging the latest cloud services from hyperscalers, SaaS providers, and Capgemini.
- Harness the cloud to modernize your core business processes, streamline operations, and move to agile models such as DevSecOps and FinOps.
- Unleash data to create intelligent products and services; and streamline your supply chain and manufacturing processes using 5G, artificial intelligence, machine learning, Internet of Things, and edge computing innovations.
Event Partners
HBS Healthcare Alumni Association
History
The Harvard Business School Healthcare Alumni Association (HBSHAA) was established in November 1999 to help bring together those who work in every part of the healthcare industry and in every part of the world.
The idea to launch this alumni organization was initiated by Bunny Ellerin, MBA 1995. Prior to the founding of this club, Harvard Business School had never had an industry-specific alumni association. Ms. Ellerin felt that just as the geographic HBS clubs bring graduates who live near each other in contact, the HBSHAA would enable healthcare industry alumni to meet and maintain contact more easily.
Mission
The Harvard Business School Healthcare Alumni Association (HBSHAA) exists to promote interaction and communication among HBS alumni involved in all sectors of the worldwide healthcare industry to aid in their professional development and continuing education. The Association strives to play an active role in positioning HBS and its alumni to achieve a leadership position in the management of healthcare and life sciences organizations.
Vision
To create a self-sustaining organization that provides members with access to resources and knowledge not easily obtained elsewhere and provides them with significant long-term value.
Objectives
Host events that provide members with access to industry leaders and expertise
Create a superior online environment that promotes information and knowledge sharing
Disseminate career and professional opportunities
Serve as a resource for HBS students interested in pursuing healthcare careers
Assist HBS faculty in need of real world perspectives or case sites
Communicate developments in healthcare research at HBS
HBS alumni are involved in some of the most exciting companies, research and breakthroughs in healthcare. This organization provides an organized forum for them to communicate, interact and exchange ideas to aid in professional development and ongoing learning. The rapid growth and success of HBSHAA has validated our premise for organizing and led to the formation of other industry-specific groups.
NYC Healthcare Business Leaders
Our History
In 2009, Bunny Ellerin and Dr. Yin Ho grew frustrated that New York City’s healthcare economy was often overlooked as a center of innovation and excellence, by outsiders and from within the city itself. They believed the city provides an ideal environment for the healthcare industry, offering expertise across all sectors plus access to capital.
So they launched NYC Health Business Leaders that year, and since then, the organization has evolved into one of the largest, most prestigious health-related networks today.
Our Mission
As NYC Health Business Leaders has evolved, our focus has grown beyond NYC, to healthcare in the New York region and nationally.
Today, we aim to bring together the best minds to discuss important issues and spur innovation. That means igniting the right conversations and connections with leading executives, entrepreneurs and physicians – true innovators with the desire and experience to have an impact. We believe that together, across sectors and levels, we are able to advance all sides of health.
Please note that the event will be recorded and live streamed and that participation in the event is agreement and authorization that your image and likeness can be used in all forms of media. This authorization acknowledges that there is no compensation for the use of your image and that all claims for compensation now and in the future are willingly relinquished without any form of arbitration or legal entitlement for review or adjudication.
Weblink:
https://www.eventbrite.com/e/423685884887
Angel Capital Association Sept 14 2022
Healthcare Innovation and the Angel Investor
Live Air Date: Wednesday, September 14, 12:00 to 1:00p Eastern
Healthcare Innovation: What’s Next for the Angel Investor
This webinar will cover a wide range of topics related to the investing in a healthcare startup and features an incredible member of the angel community, Dr. D. Martin Gershon.
Webinar objectives will be:
- To increase awareness about how healthcare start-ups are driven by scientific breakthroughs to deliver better healthcare to patients.
- To break down barriers that investors have to healthcare investment including understanding the technical/scientific complexities, regulations and IP.
- To define the potential ROI in healthcare investing, while simultaneously mitigating risk.
Dr. Martin Gershon is the Managing Partner of the Endeavor Life Sciences Venture Fund I and II, investing in great entrepreneurs and life science companies that possess innovative technologies and strong commercial potential.
Dr. Gershon has 20 years of experience as a neuroscientist, oncologist/immunologist, healthcare economist, and FDA healthcare regulatory attorney, with expertise in drug and device approval processes, clinical research, and pricing and reimbursement.
Amongst his accomplishments Dr. Gershon is a Standard & Poor’s Healthcare Industry Leader, Harvard Business School Healthcare Alumni Association member, and has served as an Advisory Board Member of Pictet Asset Managment, Chairman of the Aspen Institute Business of Health Program, Aspen Institute Senior Fellow, and Memorial Sloan-Kettering Cancer Center Mayday Fellow and has been a Senior Advisor to McKinsey & Co., Goldman Sachs, Bain Capital, Texas Pacific Group, GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Novartis, BlackRock, Caxton Associates, Pictet Group, Merrill Lynch, UBS, SG Cowen, Tiger Global, Fidelity Investments, the William J. Clinton Foundation, the Federal Reserve Board of Governors, and the Rockefeller Foundation.
Dr. Gershon has been featured as a leading expert in healthcare and life science investment on CNBC and has been a speaker at numerous conferences including the Harvard Business School Health Industry Alumni Conference, and is an Adjunct Professor of Healthcare Economics and Policy at Johns Hopkins University, Guest Lecturer of Healthcare Finance abd Drug Development at Harvard University and MIT Sloan Business School, Assistant Professor of Healthcare Economics and Finance at Columbia University, Visiting Scholar Lecturer of Healthcare Economics and Policy at McGill University, Advisor in Entrepreneurship to the NYU Stern School of Business, Berkeley Center for Entrepreneurial Studies, Columbia University School of Business, Eugene M. Lang Center for Entrepreneurship, and Harvard Innovation Labs.
*ACA Webinars are always free to members. There is a small fee for non-members to attend and receive the archive.
If you’re not yet a member, but would like to attend the webinar at the member rate, please join here prior to purchasing your ticket.
